Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, including Alcohol Use Disorder (AUD). The U.S. Senate’s move to encourage the FDA to develop new endpoints for AUD, such as reduced cravings, to enhance the regulatory pathway for new pharmaceutical candidates strongly reinforces Adial’s clinical development strategy for AD04, its lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of AUD in individuals with heavy drinking and select genotypes.

Read more at globenewswire.com